Injectable Semaglutide Shows Early Promise to Improve Fertility in Women with PMOS

Injectable semaglutide shows early promise to improve fertility in women with PMOS

Researchers at the University of Colorado Anschutz have published a proof-of-concept study in Fertility and Sterility demonstrating that injectable semaglutide may offer meaningful reproductive benefits for women with polyendocrine metabolic ovarian syndrome (PMOS), formerly known as polycystic ovary syndrome (PCOS).

Injectable Semaglutide Shows Early Potential to Enhance Fertility in Women

In a groundbreaking development poised to reshape the therapeutic landscape for women grappling with complex endocrine disorders, researchers at the University of Colorado Anschutz Medical Campus have illuminated the potential of injectable semaglutide to deliver significant reproductive and metabolic benefits to individuals affected by polyendocrine metabolic ovarian syndrome (PMOS). This condition, historically recognized as polycystic ovary s…